CorMedix (NASDAQ:CRMD) Earns Buy Rating from D. Boral Capital
D. Boral Capital reaffirmed their buy rating on shares of CorMedix (NASDAQ:CRMD – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $15.00 target price on the stock. Several other research analysts have also commented on CRMD. Royal Bank of Canada lifted their price target on CorMedix […]
D. Boral Capital reaffirmed their buy rating on shares of CorMedix (NASDAQ:CRMD – Free Report) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $15.00 target price on the stock. Several other research analysts have also commented on CRMD. Royal Bank of Canada lifted their price target on CorMedix […]
